» Articles » PMID: 25512472

The SAPHO Syndrome: a Single-center Study of 41 Adult Patients

Overview
Journal J Rheumatol
Specialty Rheumatology
Date 2014 Dec 17
PMID 25512472
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, osteitis) is a rare disease and only a few series have been published about it. We describe the experience of a rheumatology department with a focus on the therapeutic aspects.

Methods: All cases of SAPHO fulfilling the Benhamou criteria and seen between 1992 and 2013 in our unit were retrospectively included.

Results: Forty-one patients (11 men and 30 women) were included. The average age was 45 years (20-80 yrs) at the time of diagnosis. Nineteen patients had palmoplantar pustulosis, 3 had psoriasis vulgaris, 3 had severe acne, and 15 had no dermatological involvement. Bone symptoms involved mainly the anterior chest wall (n = 28, 68%), followed by the spine (n = 16, 39%) and sacroiliac joints (n = 12, 29%). Four patients had peripheral osteitis and 2 had mandibular osteitis. Ten patients had peripheral arthritis affecting mainly the knees and wrists. None of the 36 patients tested was HLA-B27-positive. At least a partial response was achieved with colchicine, methotrexate, or sulfasalazine in 0/6, 2/4, and 1/6 of patients, respectively. Antibiotic therapy (azithromycin, n = 7; doxycycline, n = 2) was effective in 2/9 patients. Pamidronate was prescribed in 26 patients with bone involvement and 18/22 patients evaluable at 6 months responded to this therapy. Two patients were treated with tumor necrosis factor blockers: 1 with infliximab and 1 with adalimumab, followed by etanercept.

Conclusion: Based on our experience, SAPHO can be diagnosed in the elderly. It was not associated with HLA-B27. Soft tissue involvement was common and the bisphosphonates were generally effective on bone involvement.

Citing Articles

What Is New and What Is Next for SAPHO Syndrome Management: A Narrative Review.

Ferraioli M, Levani J, De Luca R, Matucci-Cerinic C, Gattorno M, Guiducci S J Clin Med. 2025; 14(4).

PMID: 40004896 PMC: 11856149. DOI: 10.3390/jcm14041366.


Current and future advances in practice: SAPHO syndrome and chronic non-bacterial osteitis (CNO).

Furer V, Kishimoto M, Tomita T, Elkayam O, Helliwell P Rheumatol Adv Pract. 2024; 8(4):rkae114.

PMID: 39411288 PMC: 11474108. DOI: 10.1093/rap/rkae114.


Risankizumab Efficacy in Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Remission: A Case Report on Rheumatologic and Dermatologic Disease Manifestations with Literature Review.

Ferraioli M, Fiannacca L, Greco E, Cela E, Fatica M, Bergamini A Case Reports Immunol. 2024; 2024:9076852.

PMID: 38533274 PMC: 10965285. DOI: 10.1155/2024/9076852.


A statistical symptomatic evaluation on SAPHO syndrome from 56 cases of confirmed diagnosis and 352 cases of non-SAPHO involvement.

Qiu C, Li M, Wu Q, Zhou J, Liu T, Li J Clin Rheumatol. 2024; 43(5):1763-1775.

PMID: 38446355 DOI: 10.1007/s10067-024-06887-7.


Treatment and monitoring of SAPHO syndrome: a systematic review.

Li S, Roberts E, Hedrich C RMD Open. 2023; 9(4).

PMID: 38151265 PMC: 10753757. DOI: 10.1136/rmdopen-2023-003688.